USA - engelska - NLM (National Library of Medicine)

energique, inc. - aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinctoria root - unii:5ef0hwi5wu), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), eupatorium perfoliatum flowering top (unii: 1w0775vx6e) (eupatorium perfoliatum flowering top - unii:1w0775vx6e), - aconitum napellus 30 [hp_x] in 1 ml - may temporarily relieve symptoms associated with the flu such as achiness, chills, headache, and fever.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms associated with the flu such as achiness, chills, headache, and fever.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

USA - engelska - NLM (National Library of Medicine)

hyland's - aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), bellis perennis (unii: 2hu33i03uy) (bellis perennis - unii:2hu33i03uy), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), calendula officinalis flowering top (unii: 18e7415pxq) (calendula officinalis flowering top - unii:18e7415pxq), black cohosh (unii: k73e - aconitum napellus 3 [hp_x] in 1 g - temporarily relieves symptoms of pain and stiffness in neck, back, shoulders and joints: soreness, stiffness and pressure in joints: pain in fingers and hips; stiffness in knee joint; muscle soreness.

USA - engelska - NLM (National Library of Medicine)

native remedies, llc - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), calcium sulfide (unii: 1mbw07j51q) (calcium sulfide - unii:1mbw07j51q), mercurius solubilis (unii: 324y4038g2) (mercurius solubilis - unii:324y4038g2), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz), silicon dioxide (unii: etj7z6xbu4) (silicon dioxide - unii:etj7z6xbu4) - atropa belladonna 30 [hp_c] in 1 ml - relieves tooth disconfort uses: homeopathic remedy for relief of tooth discomfort and boils

USA - engelska - NLM (National Library of Medicine)

king bio inc. - hpus active ingredients, equal volumes of each ingredient in 10x, 30x and lm1potencies: aconitum napellus, apis mellifica, arnica montana, arsenicum album, belladonna, bellis perennis, bryonia, calendula officinalis, chamomilla, clematis erecta, ferrum phosphoricum, histaminum hydrochloricum, hypericum perforatum, ignatia amara, passiflora incarnata, phosphorous, rhus toxicodendron, sulphur, symphytum officinale and veratrum album., hpus flower remedies: clematis vitalba, flos, impatiens glandulfera, flos, - hpus active ingredients                                           purpose equal volumes of each ingredient in 10x, 30x, and lm1 potencies: aconitum napellus...............................................fears, tension, occasional anxiety apis mellifica......................................................apathy and indifference arnica montana...................................................over-sensitivity, trauma arsenicum album.................................................tension, restlessness, exhaustion belladonna...........................................................agitation, excited  mental states bellis perennis......................................................sore muscles, bruises, aching bryonia................................................................irritability calendula officinalis..............................................nervousness, trauma chamomilla .........................................................weepiness, sensitivity clematis erecta...........................

USA - engelska - NLM (National Library of Medicine)

legacy pharma inc. - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. belladonna and opium suppositories are used for relief of moderate to severe pain associated with ureteral spasm not responsive to non-narcotic analgesics and to space intervals between injections of opiates.  belladonna and opium suppositories are for rectal use only. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve belladonna and opium suppositories  for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesic not recommended for use in children 12 years of age and under belladonna and opium suppositor

USA - engelska - NLM (National Library of Medicine)

bryant ranch prepack - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve belladonna and opium suppositories for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. there are no available data with belladonna and opium suppositories in pregnant women to inform a drug associated risk for major birth defects and miscarriage. clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. the onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see warnings and precautions (5.3) ]. belladonna refers to plant alkaloids that contain anticholinergic agents such as atropine. atropine used in human pregnancies has not been associated with birth defects or adverse fetal effects although the drug readily crosses the placenta. use during pregnancy may increase risk of respiratory abnormalities, hypospadias, and eye or ear malformations but causal relationship is unclear. the collaborative perinatal project found no relationship between first trimester use of atropine and birth defects in the offspring but found an increase in birth defects in general in the offspring of pregnancies where the mother had taken belladonna. there was no relationship to any particular syndrome of anomalies. a statistically significant (although weak) association was discovered between congenital anomalies and maternal use of belladonna. a study was conducted based on the infants of 554 women who took belladonna during the first four months of pregnancy. the study was conducted in the collaborative perinatal project and showed that belladonna is unlikely to cause minor congenital abnormalities. the estimated maximum risk is most likely less than 3% if maternal belladonna is used early in pregnancy.1 labor or delivery opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. an opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. belladonna and opium suppositories is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. opioid analgesics, including belladonna and opium suppositories, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. however, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression. risk summary the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for belladonna and opium suppositories and any potential adverse effects on the breastfed infant from belladonna and opium suppositories or from the underlying maternal condition. clinical considerations infants exposed to belladonna and opium suppositories through breast milk should be monitored for excess sedation and respiratory depression. withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped. infertility chronic use of opioids may cause reduced fertility in females and males of reproductive potential. it is not known whether these effects on fertility are reversible [see adverse reactions (6.1)]. the safety and effectiveness of belladonna and opium suppositories in pediatric patients have not been established. elderly patients (aged 65 years or older) may have increased sensitivity to belladonna and opium. in general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. titrate the dosage of belladonna and opium suppositories slowly in geriatric patients [see warnings and precautions (5.2) ]. belladonna and opium suppositories contains opium, a schedule ii controlled substance. belladonna and opium suppositories contains opium, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. belladonna and opium suppositories can be abused and is subject to misuse, addiction, and criminal diversion [see warnings and precautions (5.1) ]. all patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use. prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. “drug-seeking” behavior is very common in persons with substance use disorders. drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. abuse and addiction are separate and distinct from physical dependence and tolerance. health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. in addition, abuse of opioids can occur in the absence of true addiction. belladonna and opium suppositories, like other opioids, can be diverted for non-medical use into illicit channels of distribution. careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. risks specific to abuse of belladonna and opium suppositories belladonna and opium suppositories are for rectal use only. abuse of belladonna and opium suppositories poses a risk of overdose and death. the risk is increased with concurrent abuse of belladonna and opium suppositories with alcohol and other central nervous system depressants. parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and hiv. both tolerance and physical dependence can develop during chronic opioid therapy. tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects. physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), or partial agonists (buprenorphine). physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. belladonna and opium suppositories should not be abruptly discontinued [see dosage and administration (2.4) ]. if belladonna and opium suppositories is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see use in specific populations (8.1) ].

USA - engelska - NLM (National Library of Medicine)

bryant ranch prepack - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), opium (unii: 37m3mz001l) (opium - unii:37m3mz001l) - belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve belladonna and opium suppositories for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. there are no available data with belladonna and opium suppositories in pregnant women to inform a drug associated risk for major birth defects and miscarriage. clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. the onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see warnings and precautions (5.3) ]. belladonna refers to plant alkaloids that contain anticholinergic agents such as atropine. atropine used in human pregnancies has not been associated with birth defects or adverse fetal effects although the drug readily crosses the placenta. use during pregnancy may increase risk of respiratory abnormalities, hypospadias, and eye or ear malformations but causal relationship is unclear. the collaborative perinatal project found no relationship between first trimester use of atropine and birth defects in the offspring but found an increase in birth defects in general in the offspring of pregnancies where the mother had taken belladonna. there was no relationship to any particular syndrome of anomalies. a statistically significant (although weak) association was discovered between congenital anomalies and maternal use of belladonna. a study was conducted based on the infants of 554 women who took belladonna during the first four months of pregnancy. the study was conducted in the collaborative perinatal project and showed that belladonna is unlikely to cause minor congenital abnormalities. the estimated maximum risk is most likely less than 3% if maternal belladonna is used early in pregnancy.1 labor or delivery opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. an opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. belladonna and opium suppositories is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. opioid analgesics, including belladonna and opium suppositories, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. however, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression. risk summary the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for belladonna and opium suppositories and any potential adverse effects on the breastfed infant from belladonna and opium suppositories or from the underlying maternal condition. clinical considerations infants exposed to belladonna and opium suppositories through breast milk should be monitored for excess sedation and respiratory depression. withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped. infertility chronic use of opioids may cause reduced fertility in females and males of reproductive potential. it is not known whether these effects on fertility are reversible [see adverse reactions (6.1)]. the safety and effectiveness of belladonna and opium suppositories in pediatric patients have not been established. elderly patients (aged 65 years or older) may have increased sensitivity to belladonna and opium. in general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. titrate the dosage of belladonna and opium suppositories slowly in geriatric patients [see warnings and precautions (5.2) ]. belladonna and opium suppositories contains opium, a schedule ii controlled substance. belladonna and opium suppositories contains opium, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. belladonna and opium suppositories can be abused and is subject to misuse, addiction, and criminal diversion [see warnings and precautions (5.1) ]. all patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use. prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. “drug-seeking” behavior is very common in persons with substance use disorders. drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. abuse and addiction are separate and distinct from physical dependence and tolerance. health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. in addition, abuse of opioids can occur in the absence of true addiction. belladonna and opium suppositories, like other opioids, can be diverted for non-medical use into illicit channels of distribution. careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. risks specific to abuse of belladonna and opium suppositories belladonna and opium suppositories are for rectal use only. abuse of belladonna and opium suppositories poses a risk of overdose and death. the risk is increased with concurrent abuse of belladonna and opium suppositories with alcohol and other central nervous system depressants. parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and hiv. both tolerance and physical dependence can develop during chronic opioid therapy. tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects. physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), or partial agonists (buprenorphine). physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. belladonna and opium suppositories should not be abruptly discontinued [see dosage and administration (2.4) ]. if belladonna and opium suppositories is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see use in specific populations (8.1) ].

USA - engelska - NLM (National Library of Medicine)

speer laboratories, llc - atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), capsicum (unii: 00uk7646fg) (capsicum - unii:00uk7646fg), quinine arsenite (unii: 42qo5p0nlm) (quinine - unii:a7v27phc7a), arabica coffee bean (unii: 3sw678mx72) (arabica coffee bean - unii:3sw678mx72), gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii - atropa belladonna 10 [hp_x] in 59 ml - uses : temporarily relieves symptoms of: - headache pain (throbbing, splitting, tight, dull, sick, bursting, sinus, congestive, migraine, occiptal, etc) - band feeling around the head - morning headache - sun headache uses: temporarily relieves symptoms of: headache pain (throbbing, splitting, tight, dull, sick, bursting, sinus, congestive, migraine, occipital, etc), band feeling around the head, morning headache, sun headache.

USA - engelska - NLM (National Library of Medicine)

natural creations, inc. - aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), eupatorium perfoliatum flowering top (unii: 1w0775vx6e) (eupatorium perfoliatum flowering top - unii:1w0775vx6e), ferrum phosphoricum (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), gel - aconitum napellus 30 [hp_x] in 1 ml - uses: temporarily relieves flu-like symptoms.** uses: temporarily relieves flu-like symptoms.**

USA - engelska - NLM (National Library of Medicine)

genexa llc - gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), pulsatilla pratensis (unii: 8e272251di) (pulsatilla pratensis - unii:8e272251di), onion (unii: 492225q21h) (onion - unii:492225q21h), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), euphrasia stricta (unii: c9642i91wl) (euphrasia stricta - unii:c9642i91wl), toxicodendron pubescens shoot (unii: 46pyz1f82m) - gelsemium sempervirens root 12 [hp_x] - purpose sneezing and runny nose dry cough and wet cough sinus pain nasal congestion and discharge headache chest congestion and stuffy nose mucus and loss of smell and taste restless sleep sore throat and dry throat uses* addresses symptoms associated with the common cold, such as: - chest congestion - nasal congestion - runny nose - cough - sore throat - sneezing *these "uses" are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. stop use and ask a doctor if symptoms persist for more than 3 days or worsen.